Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel

[1]  R. Kerbel,et al.  Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect , 2016, Nature Reviews Clinical Oncology.

[2]  Nicolas André,et al.  Computational oncology — mathematical modelling of drug regimens for precision medicine , 2016, Nature Reviews Clinical Oncology.

[3]  Y. Ohe,et al.  Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung Cancer. , 2016, Clinical Therapeutics.

[4]  B. Monk,et al.  Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. , 2016, The New England journal of medicine.

[5]  Min Kyoon Kim,et al.  In Vivo Tumor Growth Rate Measured by US in Preoperative Period and Long Term Disease Outcome in Breast Cancer Patients , 2015, PloS one.

[6]  M. Colleoni,et al.  Clinical overview of metronomic chemotherapy in breast cancer , 2015, Nature Reviews Clinical Oncology.

[7]  C. Punt,et al.  Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group , 2015, The Lancet.

[8]  P. Sorger,et al.  Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold , 2015, Molecular Systems Biology.

[9]  Yong Xu,et al.  Lessons from patient-derived xenografts for better in vitro modeling of human cancer. , 2014, Advanced drug delivery reviews.

[10]  B. Kaina,et al.  DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. , 2013, Cancer letters.

[11]  P. Marchetti,et al.  Metronomic chemotherapy for cancer treatment: a decade of clinical studies , 2013, Cancer Chemotherapy and Pharmacology.

[12]  J. Jang,et al.  Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma , 2011, Experimental & Molecular Medicine.

[13]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[14]  O. Dizdar,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[15]  T. Klingebiel,et al.  Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS‐96 trial , 2008, Pediatric blood & cancer.

[16]  Timothy W. Secomb,et al.  Cell Cycle Checkpoint Models for Cellular Pharmacology of Paclitaxel and Platinum Drugs , 2008, The AAPS Journal.

[17]  T. Secomb,et al.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. , 2005, Neoplasia.

[18]  L. Attardi,et al.  The role of apoptosis in cancer development and treatment response , 2005, Nature Reviews Cancer.

[19]  F. Kabbinavar,et al.  Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen‐independent prostate carcinoma , 2004, Cancer.

[20]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E Glatstein,et al.  High-time chemotherapy or high time for low dose. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Gabriele Bergers,et al.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.

[23]  S N Gardner,et al.  A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.

[24]  J. Turchi,et al.  Cisplatin-induced Apoptosis Proceeds by Caspase-3-dependent and -independent Pathways in Cisplatin-resistant and -sensitive Human Ovarian Cancer Cell Lines Proteolytic Degradation of Procaspase-3 Was Observed in Both the Cp70 and C30 Cells following Ic 50 Cisplatin Treatment, Whereas No Pro- Teolyze , 2022 .

[25]  W R Greco,et al.  Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. , 1998, Cancer research.

[26]  M. Wientjes,et al.  Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. , 1998, Cancer research.

[27]  E. Glatstein,et al.  Back to the basics: the importance of concentration x time in oncology. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  I W Taylor,et al.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. , 1983, Cancer research.

[29]  William J. Jusko,et al.  A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[30]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[31]  Evelyn D. Lobo,et al.  Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro , 2008, AAPS PharmSci.

[32]  N. Saijo,et al.  Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay , 2004, Cancer Chemotherapy and Pharmacology.

[33]  J. Au,et al.  A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect , 2000, Cancer Chemotherapy and Pharmacology.